Dabur India Ltd.    
06 Oct 2020
517.45
-0.33%
Axis Direct
We value Dabur at 50x FY23E EPS at a discount to its 3 year avg. PE of 53x given its market leadership in Ayurvedic category, rich legacy, fearlessness in NPD launches, healthy margins and operating cash flows. We initiate coverage with a BUY rating and TP of Rs. 610/share.
default
Number of FIIs/FPIs holding stock fell by 8 to 760 in Sep 2020 qtr.
Dabur India Ltd.    
21 Sep 2020
517.45
-0.33%
buy
Ventura
We initiate coverage on Dabur with a BUY for a price target of Rs.600 representing a potential appreciation of 22 % over the next 24 month from the CMP of Rs.490.
default
Number of FIIs/FPIs holding stock fell by 8 to 760 in Sep 2020 qtr.
Dabur India Ltd.    
19 Aug 2020
517.45
-0.33%
Dabur India Ltd. is trading above all available SMAs
Dabur India Ltd.    
04 Aug 2020
517.45
-0.33%
buy
Geojit BNP Paribas
Dabur India Ltd (Dabur), a leading Indian FMCG company, is a world leader in Ayurveda with a portfolio of over 250 Herbal/Ayurvedic products. The company operates through Health Supplements, Digestives, Shampoos, Hair...
default
Number of FIIs/FPIs holding stock fell by 8 to 760 in Sep 2020 qtr.
Dabur India Ltd.    
31 Jul 2020
517.45
-0.33%
buy
Arihant Capital
Dabur India earnings were below our estimates on all fronts as Covid-19 pandemic disrupted the business performance of the company. Profit for the quarter de-grew by 6.1%YoY/+21.0% QoQ to Rs 341 Cr during Q1FY21. Consolidated revenue stood at Rs 1,980 cr ,below our estimates Rs 2,209 registering a degrowth 12.9%YoY/+6.1%QoQ. Reported EBITDA de-grew by 9.0%YoY/+18.2%QoQ to Rs 416 Cr, below our estimate of Rs...
Dabur India Ltd. is trading above all available SMAs
Dabur India Ltd.    
31 Jul 2020
517.45
-0.33%
buy
ICICI Securities Limited
The sanitisers & disinfectants space generated | 90 crore of sales in Q1 with several new products being launched. We believe the opportunity in immunity boosting products is more structural & leadership position in Chyawanprash & Honey is advantage for DIL. It gained market share in both segments by 600 bps & 300 bps, respectively, in Q1. Though growth rates in hygiene category may taper down in few quarters, the category is here to...
Dabur India Ltd. has an average target of 520.91 from 11 brokers.
Dabur India Ltd.    
31 Jul 2020
517.45
-0.33%
Nirmal Bang Institutional
Robust performance; poised to deliver growth for rest of FY21 Downgrade to ACCUMULATE Daburs 1QFY21 consolidated revenue declined by 12.9% YoY to Rs19.8bn (vs our est. 13.7% decline to Rs19.6bn). Domestic FMCG business declined by 6.9% YoY, with volume declining by 9.7% YoY. International Business declined by 21.6% YoY, contributing 26.2% to overall sales during the quarter versus 29.3% in the base quarter. In the domestic FMCG business, Healthcare business grew by 29.2% YoY, Home & Personal care declined by 14.9% YoY and Foods declined by 34.4% YoY. Dabur continued to gain market share across all key categories like Chyawanprash (+600bps), Honey (+300bps), Toothpaste (+60bps) and Packaged Juices &...
Dabur India Ltd. is trading above all available SMAs
Dabur India Ltd.    
30 Jul 2020
517.45
-0.33%
Prabhudas Lilladhar
July sales up 5-6%, no trade inventory build-up, MT/CSD under pressure. We are increasing FY21/22/23 EPS estimates of Dabur India by 8%/5.7%/4.3% following sales PAT beat in 1Q mainly led by Rs1.4bn incremental sales from new launches in Sanitizers and Healthcare products. Dabur is currently riding on rising consumer demand for immunity boosters and hygiene products...
Dabur India Ltd.'s price crossed above SMA30 today
Dabur India Ltd.    
29 Jun 2020
517.45
-0.33%
Motilal Oswal
Sales from new launches are targeted to reach ~5% of total sales in 2 years (from Mr. Malhotra believes that currently Dabur is less efficient than peers on several operating costs. is likely to see growth compared to the weak outlook 2-3 quarters ago due to the companys focus on Naturals and Ayurveda in current Dabur has introduced Sanitize brand. In a highly encouraging move, Mr. Malhotra stated that they aim to match or surpass the best domestic peers on the technology and analytics front in the next April and first half of May was a setback due to supply chain issues given the lack of clarity on classification of essential/non-essential items, particularly in the case of Ayurvedic products.
Dabur India Ltd. is trading above all available SMAs
Dabur India Ltd.    
09 Jun 2020
517.45
-0.33%
Axis Direct
We recommend a BUY on DABUR INDIA with a Target Price of Rs 504, an upside of 6% from CMP of Rs. 471 and Stop Loss Rs. 455.
Dabur India Ltd.'s price crossed above SMA30 today